Antengene announces xpovio® (selinexor) data to be presented at the upcoming 2022 european hematology association hybrid congress

Shanghai and hong kong , may 13, 2022 /prnewswire/ -- antengene corporation limited ("antengene" sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announces that an abstract related to xpovio® (selinexor)  has been selected for presentation at the upcoming 2022 european hematology association (eha2022) hybrid congress taking place from june 9-12, 2022 in vienna, austria  in person or via virtual attendance: https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/ the abstract highlights encouraging activity of selinexor plus low-dose dexamethasone  combo (sd regimen) in a small group of heavily pre-treated patients relapsed/refractory multiple myeloma (r/r mm) previously exposed to chimeric antigen receptor t-cell (car-t) therapy within the single-arm, phase ii, registrational march study conducted in china. "antengene has made it a priority to focus on developing therapies for relapsed and refractory patients with cancer.
KPTI Ratings Summary
KPTI Quant Ranking